Cyberonics' VNS Therapy gains approval in Japan
This article was originally published in The Gray Sheet
Executive Summary
Cyberonics plans to launch its VNS Therapy vagus nerve stimulation device in Japan for drug-resistant epilepsy once it receives final reimbursement authorization, the company said in announcing marketing clearance from Japan's Ministry of Health, Labor and Welfare on Jan. 19. The Japanese market entry is part of Cyberonics' plan to double sales within five years, the company said last month (1"The Gray Sheet" Dec. 14, 2009)
You may also be interested in...
Cyberonics' Ambitious 5-Year Plan: Double Sales With New VNS Components
Cyberonics aims to double its sales to $320 million over the next five years by improving and adding new features to its VNS Therapy vagus nerve stimulation implant and entering new markets like Japan
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.